Company Overview and News
In this day and age, dividend investors looking for high-dividend stocks shouldn’t limit themselves to U.S. companies only. Some of the best dividend stocks over time have been foreign issuers. And that’s still the case at the moment.
STZ.B BUD GIS GE GEC RDS.B PG UL RDS.A UN XOM LYB RDSB STZ RDSA GSK BP JPM KHC RYDBF KO GNE RYDAF DEO
Roche Holding AG (RHHBY - Free Report) announced that the FDA has approved expansion prefilled syringe formulation of its asthma drug, Xolair(omalizumab). Xolair is approved for use in a 75 mg/0.5 mL and 150 mg/1 mL single-dose PFS formulation for both the approved indications of the drug - allergic asthma and chronic idiopathic urticaria (chronic hives without a known cause). Xolair is currently available in a 150 mg single-dose vial with lyophilized, sterile powder for reconstitution.
AZN RHHVF AZN RHHBY NVS GSK GSK HSIC RHHBF
CytoDyn, Inc. (OTCQB:CYDY) is a transforming company. CytoDyn recently announced the definitive agreement to close the ProstaGene acquisition on August 28, 2018. This deal will allow ProstaGene to utilize CytoDyn’s PRO 140, a CCR5 inhibitor, for cancer clinical trials. On any number of metrics, this deal was done on a very forward-looking basis. In retrospect, this could have been one of the biggest bargains in cancer research consummated.
CYDY GILD GSK GSK PFE
2018-10-01 sec.gov - 1
Blueprint FORM 6-K
2018-09-27 sec.gov - 1
Blueprint FORM 6-K
2018-09-27 japantimes.co.jp - 1
SAN, FRANCISCO/HONG KONG – For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his 2-week-old drug company.
BABA GSK GSK
GlaxoSmithKline plc (GSK - Free Report) and Aeras, a non-profit organization, announced positive primary results from a phase IIb study evaluating vaccine candidate, M72/AS01E, in HIV-negative patients with latent tuberculosis infection. The initial data from the study showed that the vaccine candidate led to a significant reduction in incidence of pulmonary tuberculosis disease in the patient population.
JNJ GSK GSK
Shares of Theravance Biopharma, Inc. (TBPH - Free Report) rallied 5.3% on positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”), the scientific committee of the European Medicines Agency (“EMA”), for the label expansion of GlaxoSmithKline’s (GSK - Free Report) COPD drug, Trelegy Ellipta. Glaxo is seeking approval for Trelegy Ellipta in a broader patient population who are not adequately treated by a long-acting muscarinic antagonist (“LAMA”) and long-acting beta2-agonist (“LABA”).
TBPH INVA GSK GSK
Gilead Sciences, Inc. (GILD - Free Report) announced that it plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments — Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg).
GILD GSK ABBV GSK ABBV
Investors focused on the Medical space have likely heard of GlaxoSmithKline plc (GSK - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GSK and the rest of the Medical group's stocks.
The First Trust STOXX European Select Dividend Index Fund (FDD - Free Report) made its debut on 08/27/2007, and is a smart beta exchange traded fund that provides broad exposure to the European Equity ETFs category of the market.
RDS.B RDS.A RYDBF GSK IQDE RDSB IQDF RDSA RYDAF GSK
Novartis AG (NVS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Gilenya for the treatment of children and adolescents aged 10 to 17 years with relapsing remitting forms of multiple sclerosis (RRMS).
REGN RDN NVS GSK GSK ONCE
SAN FRANCISCO/HONG KONG, Sept 24 (Reuters) - For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.
BABA GSK GSK
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to GSK / GlaxoSmithKline plc on message board site Silicon Investor.
as of ET